Uganda’s dual approach to tackle type 1 diabetes in children and young people

For the online media outlet Focus On Uganda, Mathias Kirunda writes about efforts to tackle type 1 diabetes among children and young people in Uganda, highlighting challenges and initiatives improving access to care in underserved areas, as outlined in the Foundation’s newly released report.

The article highlights the challenges and efforts to tackle type 1 diabetes (T1D) among children and young people (CYP) in low- and middle-income countries (LMICs), with a focus on Uganda. It draws on the Foundation’s latest report, which reviews 11 company-led initiatives supported by four companies— Biocon, Eli Lilly, Novo Nordisk and Sanofi —that provide vital diabetes care in underserved areas. For many CYP, these initiatives are often the only source of treatment.

The article highlights findings on Uganda, noting it as one of 20 LMICs receiving insulin donations through the Changing Diabetes in Children (CDiC) initiative, supported by Novo Nordisk. Between 2009 and 2016, CDiC, the World Diabetes Foundation (WDF), and Uganda’s Ministry of Health established seven T1D clinics, trained healthcare workers, and provided education to families across urban and rural areas.

The article also notes Uganda’s participation in the Virtual Buddy Doctor initiative, part of the iCARE programme, an inclusive business model backed by Novo Nordisk. This platform connects diabetes specialists with local providers to deliver virtual training and peer support, particularly in remote areas. While not specifically designed for CYP, some are likely benefitting from these broader efforts.

Despite these initiatives, the article highlights ongoing barriers to sustainable care. It cites report data showing that just 8% of the estimated 825,000 CYP in need across 71 LMICs have been reached with insulin and supplies. This shortfall underscores the urgent need to scale up access, expand product availability, and build long-term care systems.